NEW YORK (GenomeWeb) – Biodesix said today that it has acquired Seattle-based Integrated Diagnostics.

Financial terms of the deal were not disclosed.

The acquisition adds Indi's XL2 lung cancer test to Biodesix's portfolio. A second generation technology of what was previously called Xpresys Lung, the XL2 test measures two protein markers in the blood, which, combined with other pathologic and clinical factors, can improve the identification of cancers in individuals who have had a lung nodule detected via imaging.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.